Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation

See allHide authors and affiliations

Science  18 Jan 2019:
Vol. 363, Issue 6424, pp. 288-293
DOI: 10.1126/science.aat0066

Serotherapy treats a transplant hurdle

Cytomegalovirus (CMV) infection and reactivation are common and potentially fatal complications after bone marrow or hematopoietic stem cell transplantation (BMT). Martins et al. developed faithful preclinical murine models of CMV reactivation following BMT and found that humoral immunity can prevent this process (see the Perspective by Alegre). After BMT, antiviral antibodies that would have kept CMV at bay dwindle because host plasma cells are ablated and the donor B cell pool reconstitutes poorly. CMV reactivation was prevented by transferring antibody-containing immune serum. Such a therapeutic strategy would avoid some limitations of cellular therapies for BMT patients.

Science, this issue p. 288; see also p. 232

View Full Text

Stay Connected to Science